Page 363 - Haematologica Vol. 109 - July 2024

CASE REPORT
and 5Department of Microbiology and Immunology, University of Maryland, Baltimore, MD, USA
Correspondence:
M. H. KOCOGLU - mkocoglu@som.umaryland.edu https://doi.org/10.3324/haematol.2023.284793
Received: December 5, 2023. Accepted: February 15, 2024. Early view: February 22, 2024.
©2024 Ferrata Storti Foundation Published under a CC BY-NC license
Disclosures
PGR has received research funding from Jazz pharmaceuticals. The remaining authors have no conflicts of interest to disclose.
References
1. Atanackovic D, Luetkens T, Omili D, et al. Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy. Blood. 2022;140(2):152-156.
2. Dahiya S, Luetkens T, Lutfi F, et al. Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy. Blood Adv. 2022;6(2):686-689.
3. Atanackovic D, Kreitman RJ, Cohen J, et al. T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine. J Immunother Cancer. 2022;10(7):e004953.
4. Richardson PG, Carreras E, Iacobelli M, Nejadnik B. The use of defibrotide in blood and marrow transplantation. Blood Adv. 2018;2(12):1495-1509.
5. Nauffal M, Kim HT, Richardson PG, et al. Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant. Blood Adv. 2022;6(1):181-188.
6. Eissner G, Hartmann I, Kesikli A, et al. CD4+CD25+FoxP3+ regulatory T cells enhance the allogeneic activity of endothelial- specific CD8+/CD28-CTL. Int Immunol. 2011;23(8):485-492.
7. Strouse C, Richardson P, Prentice G, et al. Defibrotide for treatment of severe veno-occlusive disease in pediatrics and adults: an exploratory analysis using data from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2016;22(7):1306-1312.
8. Palomo M, Mir E, Rovira M, Escolar G, Carreras E, Diaz-Ricart M. What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. Blood. 2016;127(13):1719-1727.
9. Francischetti IM, Oliveira CJ, Ostera GR, et al. Defibrotide interferes with several steps of the coagulation-inflammation
Contributions
MK designed the study, analyzed the data, prepared figures, and wrote the manuscript. PGR helped to design the study, analyze data and write the manuscript. CCM and APR analyzed data and helped to write the manuscript. DA performed experiments, analyzed the data, and prepared figures.
Funding
This study was funded by two grants from the Kahlert Foundation (to DA), by the Maryland Department of Health’s Cigarette Restitution Fund Program (to DA) and by the National Cancer Institute - Cancer Center Support Grant (CCSG) P30CA134274, and was in part supported by the Paula and Rodger Riney Foundation (to PGR and CCM).
Data-sharing statement
The data presented in this report is available upon request.
cycle and exhibits therapeutic potential to treat severe malaria.
Arterioscler Thromb Vasc Biol. 2012;32(3):786-798.
10. Fernandez S, Palomo M, Molina P, et al. Progressive endothelial
cell damage in correlation with sepsis severity. Defibrotide as a
contender. J Thromb Haemost. 2021;19(8):1948-1958.
11. Elhadad S, Redmond D, Tan A, et al. Defibrotide mitigates
endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies. Thromb Res. 2023;225:47-56.
12. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020;217(6):e20200652.
13. Shi H, Gandhi AA, Smith SA, et al. Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide. JCI Insight. 2021;6(17):e149149.
14. Ali RA, Estes SK, Gandhi AA, et al. Defibrotide inhibits antiphospholipid antibody-mediated neutrophil extracellular trap formation and venous thrombosis. Arthritis Rheumatol. 2022;74(5):902-907.
15. Onuora S. Defibrotide inhibits NET-mediated thrombosis in APS models. Nat Rev Rheumatol. 2022;18(2):63.
16. Frame D, Scappaticci GB, Braun TM, et al. Defibrotide therapy for SARS-CoV-2 ARDS. Chest. 2022;162(2):346-355.
17. Garcia-Bernal D, Palomo M, Martinez CM, et al. Defibrotide inhibits donor leucocyte-endothelial interactions and protects against acute graft-versus-host disease. J Cell Mol Med. 2020;24(14):8031-8044.
18. Richardson E, Garcia-Bernal D, Calabretta E, et al. Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. Expert Opin Ther Targets. 2021;25(6):423-433.
Haematologica | 109 July 2024
2377